B Kallmünzer1, A Beck, S Schwab, R Kollmar. 1. Neurologische Klinik der Friedrich-Alexander-Universität Erlangen-Nürnberg, Schwabachanlage 6, Erlangen, Germany.
Abstract
BACKGROUND: Fever in acute stroke is associated with poor prognosis, but evidence-based recommendations on antipyretic therapy are lacking. METHODS: A nation-wide survey was carried out among all certified stoke units in Germany about principles and organization of antipyretic strategies. RESULTS: In all cases antipyretic treatment is the standard of care. The use of paracetamol is part of the first-line therapy in 94%. In cases of non-response, distinct heterogeneity of therapeutic methods and intensities becomes apparent leading potentially to insufficient antipyretic treatment. CONCLUSION: So far, there is uncertainty about the optimal antipyretic treatment strategy after acute stroke. While current guidelines are not very explicit, efforts should be made to define a standardized, evidence-based antipyretic protocol to improve patient care, outcome on stroke units and comparability of therapeutic strategies.
BACKGROUND: Fever in acute stroke is associated with poor prognosis, but evidence-based recommendations on antipyretic therapy are lacking. METHODS: A nation-wide survey was carried out among all certified stoke units in Germany about principles and organization of antipyretic strategies. RESULTS: In all cases antipyretic treatment is the standard of care. The use of paracetamol is part of the first-line therapy in 94%. In cases of non-response, distinct heterogeneity of therapeutic methods and intensities becomes apparent leading potentially to insufficient antipyretic treatment. CONCLUSION: So far, there is uncertainty about the optimal antipyretic treatment strategy after acute stroke. While current guidelines are not very explicit, efforts should be made to define a standardized, evidence-based antipyretic protocol to improve patient care, outcome on stroke units and comparability of therapeutic strategies.
Authors: D W Dippel; E J van Breda; H M van Gemert; H B van der Worp; R J Meijer; L J Kappelle; P J Koudstaal Journal: Stroke Date: 2001-07 Impact factor: 7.914
Authors: H Bart van der Worp; Emily S Sena; Geoffrey A Donnan; David W Howells; Malcolm R Macleod Journal: Brain Date: 2007-05-03 Impact factor: 13.501
Authors: Heleen M den Hertog; H Bart van der Worp; H Maarten A van Gemert; Ale Algra; L Jaap Kappelle; Jan van Gijn; Peter J Koudstaal; Diederik W J Dippel Journal: Lancet Neurol Date: 2009-03-16 Impact factor: 44.182
Authors: Diederik W J Dippel; Eric J van Breda; H Bart van der Worp; H Maarten A van Gemert; Ron J Meijer; L Jaap Kappelle; Peter J Koudstaal Journal: BMC Cardiovasc Disord Date: 2003-02-06 Impact factor: 2.298